Editorial: Prevalence of Suspected Metabolic Dysfunction-Associated Liver Disease in Adolescents in the United States Using Updated Diagnostic Criteria—Authors' Reply

IF 6.7 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Alimentary Pharmacology & Therapeutics Pub Date : 2025-03-16 DOI:10.1111/apt.70092
Sheila L. Noon, Tin Bo Nicholas Lam, Jeffrey B. Schwimmer
{"title":"Editorial: Prevalence of Suspected Metabolic Dysfunction-Associated Liver Disease in Adolescents in the United States Using Updated Diagnostic Criteria—Authors' Reply","authors":"Sheila L. Noon,&nbsp;Tin Bo Nicholas Lam,&nbsp;Jeffrey B. Schwimmer","doi":"10.1111/apt.70092","DOIUrl":null,"url":null,"abstract":"<p>We appreciate the editorial by Bonn and Xanthakos [<span>1</span>] discussing our recent study on the prevalence and predictors of suspected MASLD in US adolescents [<span>2</span>]. Their commentary highlights the importance of MASLD in paediatrics and reinforces the key questions that remain about its clinical and research application. While the transition in nomenclature from NAFLD to MASLD provides a more structured definition, its implementation in children requires further investigation.</p><p>A challenge in paediatric MASLD is misdiagnosis, especially in children with obesity whose liver disease is unrelated to steatosis. Hildreth et al. showed how autoimmune hepatitis can present with obesity, elevated ALT, and imaging findings that mimic steatosis, resulting in an erroneous MASLD diagnosis [<span>3</span>]. Conversely, our study found that 20.2% of adolescents with elevated ALT had no cardiometabolic risk factors, raising concerns that some children with liver disease may remain undetected under the updated criteria. Further complicating diagnosis, paediatric MASLD exhibits distinct histologic features, with a greater tendency for periportal inflammation and fibrosis than the pericentral pattern seen in adults [<span>4</span>]. These differences suggest MASLD in children involves unique developmental and metabolic pathways, reinforcing the need for paediatric-specific research rather than assuming direct parallels with adult disease.</p><p>Distinguishing association from causation is another key challenge in MASLD. While the definition links hepatic steatosis to metabolic dysfunction, it is unclear whether one drives the other. Hepatic fat accumulation in preschool-aged children, as described by Goyal et al., challenges the assumption that metabolic dysfunction is always the initiating factor [<span>5</span>]. If it were, it should precede hepatic steatosis. However, steatosis can appear before insulin resistance, dyslipidemia, or hypertension, suggesting it may contribute to metabolic dysfunction. Alternatively, both may share early-life determinants, such as prenatal exposures, epigenetic modifications, or perinatal nutrition patterns. Resolving these uncertainties requires longitudinal studies tracking hepatic steatosis from early childhood and would rely on repeated measures of hepatic steatosis. Currently, the only validated non-invasive tool for measuring hepatic steatosis in children is MRI-PDFF [<span>6, 7</span>]. Integrating this technology would allow us to determine whether steatosis precedes, predicts, or parallels metabolic dysfunction and help identify windows for intervention and stratify risk.</p><p>The inclusion of waist circumference in MASLD criteria aims to improve specificity by capturing central adiposity [<span>8</span>]. Malki et al. demonstrated that visceral adiposity is the strongest predictor of hepatic steatosis, supporting waist circumference as a potential surrogate [<span>9</span>]. However, our study found that among adolescents with elevated ALT, all those with an elevated waist circumference were also identified by BMI ≥ 85th percentile, meaning waist circumference did not enhance case detection. Furthermore, it is not routinely measured in paediatric practice and is subject to variability due to examiner technique and patient positioning. These factors call into question its value for MASLD diagnosis in children.</p><p>Ultimately, criteria for MASLD should be grounded in solid evidence, function well in paediatric practice, and fulfil their intended purpose of informing clinical care for this population, with special attention to ensuring accurate diagnosis and minimising misclassification in children.</p><p><b>Sheila L. Noon:</b> conceptualization, writing – original draft, writing – review and editing. <b>Tin Bo Nicholas Lam:</b> conceptualization, writing – original draft, writing – review and editing. <b>Jeffrey B. Schwimmer:</b> conceptualization, writing – original draft, writing – review and editing.</p><p>The authors' declarations of personal and financial interests are unchanged from those in the original article [<span>2</span>].</p><p>This article is linked to Noon et al. papers. To view these articles, visit https://doi.org/10.1111/apt.70022 and https://doi.org/10.1111/apt.70067.</p>","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"61 9","pages":"1557-1558"},"PeriodicalIF":6.7000,"publicationDate":"2025-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/apt.70092","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alimentary Pharmacology & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/apt.70092","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

We appreciate the editorial by Bonn and Xanthakos [1] discussing our recent study on the prevalence and predictors of suspected MASLD in US adolescents [2]. Their commentary highlights the importance of MASLD in paediatrics and reinforces the key questions that remain about its clinical and research application. While the transition in nomenclature from NAFLD to MASLD provides a more structured definition, its implementation in children requires further investigation.

A challenge in paediatric MASLD is misdiagnosis, especially in children with obesity whose liver disease is unrelated to steatosis. Hildreth et al. showed how autoimmune hepatitis can present with obesity, elevated ALT, and imaging findings that mimic steatosis, resulting in an erroneous MASLD diagnosis [3]. Conversely, our study found that 20.2% of adolescents with elevated ALT had no cardiometabolic risk factors, raising concerns that some children with liver disease may remain undetected under the updated criteria. Further complicating diagnosis, paediatric MASLD exhibits distinct histologic features, with a greater tendency for periportal inflammation and fibrosis than the pericentral pattern seen in adults [4]. These differences suggest MASLD in children involves unique developmental and metabolic pathways, reinforcing the need for paediatric-specific research rather than assuming direct parallels with adult disease.

Distinguishing association from causation is another key challenge in MASLD. While the definition links hepatic steatosis to metabolic dysfunction, it is unclear whether one drives the other. Hepatic fat accumulation in preschool-aged children, as described by Goyal et al., challenges the assumption that metabolic dysfunction is always the initiating factor [5]. If it were, it should precede hepatic steatosis. However, steatosis can appear before insulin resistance, dyslipidemia, or hypertension, suggesting it may contribute to metabolic dysfunction. Alternatively, both may share early-life determinants, such as prenatal exposures, epigenetic modifications, or perinatal nutrition patterns. Resolving these uncertainties requires longitudinal studies tracking hepatic steatosis from early childhood and would rely on repeated measures of hepatic steatosis. Currently, the only validated non-invasive tool for measuring hepatic steatosis in children is MRI-PDFF [6, 7]. Integrating this technology would allow us to determine whether steatosis precedes, predicts, or parallels metabolic dysfunction and help identify windows for intervention and stratify risk.

The inclusion of waist circumference in MASLD criteria aims to improve specificity by capturing central adiposity [8]. Malki et al. demonstrated that visceral adiposity is the strongest predictor of hepatic steatosis, supporting waist circumference as a potential surrogate [9]. However, our study found that among adolescents with elevated ALT, all those with an elevated waist circumference were also identified by BMI ≥ 85th percentile, meaning waist circumference did not enhance case detection. Furthermore, it is not routinely measured in paediatric practice and is subject to variability due to examiner technique and patient positioning. These factors call into question its value for MASLD diagnosis in children.

Ultimately, criteria for MASLD should be grounded in solid evidence, function well in paediatric practice, and fulfil their intended purpose of informing clinical care for this population, with special attention to ensuring accurate diagnosis and minimising misclassification in children.

Sheila L. Noon: conceptualization, writing – original draft, writing – review and editing. Tin Bo Nicholas Lam: conceptualization, writing – original draft, writing – review and editing. Jeffrey B. Schwimmer: conceptualization, writing – original draft, writing – review and editing.

The authors' declarations of personal and financial interests are unchanged from those in the original article [2].

This article is linked to Noon et al. papers. To view these articles, visit https://doi.org/10.1111/apt.70022 and https://doi.org/10.1111/apt.70067.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
编辑:使用最新诊断标准的美国青少年疑似代谢功能障碍相关肝病患病率——作者回复
我们感谢Bonn和Xanthakos[1]的社论,讨论了我们最近对美国青少年中疑似MASLD的患病率和预测因素的研究。他们的评论强调了MASLD在儿科中的重要性,并强调了关于其临床和研究应用的关键问题。虽然从NAFLD到MASLD的命名转变提供了更结构化的定义,但其在儿童中的实施需要进一步调查。儿科MASLD的一个挑战是误诊,特别是在肝脏疾病与脂肪变性无关的肥胖儿童中。Hildreth等人研究了自身免疫性肝炎如何表现为肥胖、ALT升高和类似脂肪变性的影像学表现,从而导致错误的MASLD诊断[3]。相反,我们的研究发现,20.2%的ALT升高的青少年没有心脏代谢危险因素,这引起了人们的担忧,即一些患有肝脏疾病的儿童可能在更新的标准下仍未被发现。进一步使诊断复杂化的是,儿童MASLD表现出明显的组织学特征,门静脉周围炎症和纤维化的倾向大于成人[4]的中心周围模式。这些差异表明,儿童MASLD涉及独特的发育和代谢途径,因此需要进行针对儿科的研究,而不是假设与成人疾病有直接的相似之处。区分关联和因果关系是MASLD的另一个关键挑战。虽然该定义将肝脂肪变性与代谢功能障碍联系起来,但尚不清楚两者之间是否有因果关系。根据Goyal等人的描述,学龄前儿童肝脏脂肪堆积挑战了代谢功能障碍总是触发因素[5]的假设。如果是,它应该先于肝脂肪变性。然而,脂肪变性可出现在胰岛素抵抗、血脂异常或高血压之前,这表明它可能导致代谢功能障碍。或者,两者可能有共同的早期生活决定因素,如产前暴露、表观遗传修饰或围产期营养模式。解决这些不确定性需要从儿童早期跟踪肝脂肪变性的纵向研究,并将依赖于肝脂肪变性的重复测量。目前,唯一经过验证的测量儿童肝脏脂肪变性的无创工具是MRI-PDFF[6,7]。整合这项技术将使我们能够确定脂肪变性是否先于、预测或与代谢功能障碍平行,并帮助确定干预窗口和分层风险。将腰围纳入MASLD标准的目的是通过捕获中心性肥胖[8]来提高特异性。Malki等人证明,内脏脂肪是肝脂肪变性的最强预测因子,支持腰围作为潜在的替代指标。然而,我们的研究发现,在ALT升高的青少年中,所有腰围升高的人也可以通过BMI≥85百分位来识别,这意味着腰围并没有提高病例的检出率。此外,在儿科实践中,它不是常规测量,并且由于检查人员的技术和患者的体位而受到变化。这些因素对其在儿童MASLD诊断中的价值提出了质疑。最终,MASLD的标准应该建立在可靠的证据基础上,在儿科实践中发挥良好的作用,并实现其为这一人群提供临床护理的预期目的,特别注意确保准确诊断和尽量减少儿童的错误分类。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
15.60
自引率
7.90%
发文量
527
审稿时长
3-6 weeks
期刊介绍: Alimentary Pharmacology & Therapeutics is a global pharmacology journal focused on the impact of drugs on the human gastrointestinal and hepato-biliary systems. It covers a diverse range of topics, often with immediate clinical relevance to its readership.
期刊最新文献
Post-Operative Recurrence of Colonic Crohn's Disease After Colectomy: The RESECOL Study by the Young Group of GETECCU. Real-World Alcohol Use Disorder Outcomes in Patients With Concurrent Metabolic Dysfunction: GLP-1 Receptor Agonists Versus FDA-Approved AUD Medications. Letter: Eating Disorders in Inflammatory Bowel Disease-Are We Asking the Right Questions? Letter: Improving the Interpretability and Portability of Tumour Burden Score-Based Prediction of Extrahepatic Progression After Transarterial Chemoembolization (TACE). Letter: Improving the Interpretability and Portability of Tumour Burden Score-Based Prediction of Extrahepatic Progression After Transarterial Chemoembolisation (TACE)-Author's Reply.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1